AngioDynamics, Inc. (NASDAQ: ANGO) today announced that the United States Food and Drug Administration (FDA) approved the Company’s investigational device ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News FDA Management Comments

AngioDynamics (ANGO) Misses Q3 EPS by 3c, Revenues Miss; Reiterates FY19 EPS/Revenue Mid-Point Guidance Below ConsensusApril 2, 2019 7:04 AM AngioDynamics Receives FDA Approval to Initiate NanoKnife® DIRECT Clinical Study for the Treatment of Stage III Pancreatic CancerApril 1, 2019 6:00 AM AngioDynamics (ANGO) Announces OARtrac Radiation Dose Monitoring System Receives Expanded FDA Clearance for Electron Radiation TherapyMarch 28, 2019 4:05 PM